Genocury Biotech
Genocury’s September 2025 announcement reports an investigator-initiated study of CD19-directed in vivo CAR-T in B-cell lymphoma. A reported individual response is preliminary and does not establish durability or comparative benefit. Current enrollment and formal regulatory trial status need confirmation.
Corporate information
- Company entity
- Genocury Biotech
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.genocury.com/news/detail/56 ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Genocury’s September 2025 announcement reports an investigator-initiated study of CD19-directed in vivo CAR-T in B-cell lymphoma. A reported individual response is preliminary and does not establish durability or comparative benefit. Current enrollment and formal regulatory trial status need confirmation.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.